newsfilter
← Latest News
GlobeNewswire·

NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK

  • Wohl & Fruchter LLP is investigating the fairness of GSK's proposed $124.00 per cash share tender offer to acquire Nuvalent, Inc. (NASDAQ: NUVL).
  • The proposed sale price falls below price targets set by multiple Wall Street analysts, including Robert W. Baird ($158.00), Guggenheim ($151.00), Truist Financial ($140.00), UBS ($138.00), Stifel Nicolaus ($135.00), & Canaccord Genuity ($126.00).
  • The law firm is examining whether the NUVL board acted in shareholders' best interests, specifically regarding the fairness of the sale price & the full disclosure of all material information & conflicts.
  • Shareholders concerned about the transaction are invited to contact Wohl & Fruchter via their website, by phone at 866-833-6245, or via email at alerts@wohlfruchter.com for a no-charge consultation.